415
Participants
Start Date
July 2, 2017
Primary Completion Date
April 8, 2024
Study Completion Date
April 8, 2024
Quavonlimab
Quavonlimab is administered intravenously (IV) during the Dose Escalation Phase and Dose Confirmation Phase at either DL1 or DL2, and is administered IV during the Efficacy Expansion Phase at DL2.
Pembrolizumab
Pembrolizumab is administered IV at PDL1 on Day 1 of each cycle starting Cycle 2 for the Dose Escalation Phase or starting Cycle 1 of the Dose Confirmation Phase. Pembrolizumab is administered IV at PDL2 on Day 1 of each cycle for the Efficacy Expansion Phase (Arm G).
Pembrolizumab/Quavonlimab
Pembrolizumab/Quavonlimab is a coformulated product composed of quavonlimab at DL1 in combination with pembrolizumab at dose level 2 (PDL2).
Auckland City Hospital ( Site 0016), Auckland
Melanoma Institute Australia ( Site 0017), Wollstonecraft
Blacktown Hospital. Western Sydney local health district ( Site 0009), Blacktown
Sandton Oncology Medical Group PTY LTD ( Site 2701), Johannesburg
Calvary Mater Newcastle ( Site 0025), Waratah
Alfred Health ( Site 0018), Melbourne
Ballarat Health Services ( Site 0022), Ballarat
Gallipoli Medical Research Foundation-GMRF CTU ( Site 0019), Brisbane
Cairns and Hinterland Hospital and Health Service ( Site 0020), Cairns
Ashford Cancer Centre Research ( Site 0012), Kurralta Park
Cape Town Oncology Trials Pty Ltd ( Site 2704), Kraaifontein
Cancercare Rondebosch Oncology ( Site 2706), Rondebosch
Canterbury District Health Board ( Site 0023), Christchurch
Hopital La Timone ( Site 3303), Marseille
Onkologikoa - Instituto Oncologico de San Sebastian ( Site 3405), Donostia / San Sebastian
Institut Bergonie ( Site 3306), Bordeaux
IRCCS Istituto Oncologico Veneto ( Site 3905), Padua
Tennessee Oncology Nashville ( Site 0004), Nashville
Hospital Universitario Virgen de la Macarena ( Site 3402), Seville
Hospital General Universitario de Valencia ( Site 3404), Valencia
Sheba Medical Center - Cancer Center ( Site 0002), Ramat Gan
Policlinico Le Scotte - A.O. Senese ( Site 3907), Siena
CHRU Lille - Hopital Claude Huriez ( Site 3302), Lille
CH Lyon Sud Hospices Civils de Lyon ( Site 3307), Pierre-Bénite
South Texas Accelerated Research Therapeutics, LLC (START) ( Site 0001), San Antonio
Istituto Nazionale Tumori Fondazione Pascale ( Site 3903), Napoli
Banner MD Anderson Cancer Center ( Site 0013), Gilbert
Gustave Roussy ( Site 3305), Villejuif
Beijing Cancer hospital-Digestive Oncology ( Site 5001), Beijing
Sir Run Run Shaw Hospital-Medical Oncology ( Site 5003), Hangzhou
Chongqing Cancer Hospital-Phase 1 Unite ( Site 5004), Chongqing
Rambam Medical Center ( Site 0003), Haifa
Fundacion Arturo Lopez Perez ( Site 5601), Santiago
Hadassah Ein Karem Hebrew University Medical Center ( Site 0021), Jerusalem
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0005), Hackensack
Inova Schar Cancer Institute ( Site 1001), Fairfax
Sunnybrook Research Institute ( Site 1103), Toronto
Princess Margaret Cancer Centre ( Site 1104), Toronto
Centre Hospitalier de l Universite de Montreal - CHUM ( Site 1102), Montreal
Jewish General Hospital ( Site 1105), Montreal
McGill University Health Centre ( Site 1101), Montreal
"Regional General Hospital of Athens Laiko ( Site 3001)", Athens
National Cancer Center Hospital East ( Site 0014), Kashiwa
Hyogo Cancer Center ( Site 0015), Akashi
Szpital Kliniczny im. Heliodora Swiecickiego Uniwers Medyczn ( Site 4803), Poznan
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Oddzial Badan Wczesnych Faz ( Site 4801, Warsaw
Asan Medical Center ( Site 0006), Seoul
Seoul National University Hospital ( Site 0007), Seoul
Severance Hospital Yonsei University Health System ( Site 0008), Seoul
Samsung Medical Center ( Site 0010), Seoul
Instituto Catalan de Oncologia ICO - Hospital Duran i Reynals ( Site 3403), L'Hospitalet de Llobregat
Hospital Clinic i Provincial de Barcelona ( Site 3401), Barcelona
Skanes Universitetssjukhus Lund. ( Site 4601), Lund
Merck Sharp & Dohme LLC
INDUSTRY